News headlines about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kura Oncology earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.2669117228447 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Kura Oncology Inc (KURA) Expected to Post FY2020 Earnings of $4.75 Per Share (americanbankingnews.com)
- BRIEF-Kura Oncology Q2 Loss Per Share $0.45 (msn.com)
- Kura Oncology’s (KURA) CEO Troy Wilson on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference (finance.yahoo.com)
- Kura Oncology (KURA) Given a $31.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
Shares of Kura Oncology stock traded down $0.10 on Friday, hitting $19.10. 112,699 shares of the company were exchanged, compared to its average volume of 208,353. Kura Oncology has a 1-year low of $5.90 and a 1-year high of $24.02. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.37 and a current ratio of 10.22.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.45). equities analysts expect that Kura Oncology will post -1.71 EPS for the current year.
KURA has been the subject of a number of research analyst reports. Cann restated a “buy” rating and issued a $27.00 target price on shares of Kura Oncology in a research note on Tuesday, April 17th. BidaskClub cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday, April 24th. ValuEngine upgraded Kura Oncology from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Oppenheimer lifted their price objective on Kura Oncology from $27.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, July 9th. Finally, HC Wainwright assumed coverage on Kura Oncology in a report on Wednesday, August 1st. They set a “buy” rating and a $31.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $27.00.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.